Neurophysiological Effects of Bitopertin in Schizophrenia

Journal of Clinical Psychopharmacology

Volumn 37, Issue 4, 2017, Pages 447-451

  Kantrowitz, Joshua T ^a,b   Nolan, Karen A ^a,c   Epstein, Michael L ^a,b,d   Lehrfeld, Nayla ^a   Shope, Constance ^a   Petkova, Eva ^a,c   Javitt, Daniel C ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b Columbia University ^*  (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

drug discovery; electrophysiology; glutamate; MMN; schizophrenia

Indexed keywords

ARIPIPRAZOLE; BITOPERTIN; FLUPHENAZINE; HALOPERIDOL; LURASIDONE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; (4-(3-FLUORO-5-TRIFLUOROMETHYLPYRIDIN-2-YL)PIPERAZIN-1-YL)(5-METHANESULFONYL-2-(2,2,2-TRIFLUORO-1-METHYLETHOXY)PHENYL)METHANONE; GLYCINE TRANSPORTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PIPERAZINE DERIVATIVE; SLC6A9 PROTEIN, HUMAN; SULFONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; EVENT RELATED POTENTIAL; FEMALE; HUMAN; MALE; MISMATCH NEGATIVITY; NEUROPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; ANTAGONISTS AND INHIBITORS; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; FEMALE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SULFONES; TREATMENT OUTCOME;

EID: 85020286218     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000722     Document Type: Article

References (35)

1. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010;83:108-121.
2. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
3. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
4. Moghaddam B, Krystal JH. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull. 2012;38:942-949.
5. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. 2005;76:1-23.
6. Light GA, Swerdlow NR, Rissling AJ, et al. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012;7:e39434.
7. Erickson MA, Ruffle A, Gold JM. A meta-analysis of mismatch negativity in schizophrenia: from clinical risk to disease specificity and progression. Biol Psychiatry. 2016;79:980-987.
8. Light GA, Swerdlow NR, Thomas ML, et al. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. 2015;163:63-72.
9. Friedman T, Sehatpour P, Dias E, et al. Differential relationships of mismatch negativity and visual p1 deficits to premorbid characteristics and functional outcome in schizophrenia. Biol Psychiatry. 2012;71: 521-529.
10. Javitt DC, Steinschneider M, Schroeder CE, et al. Role of cortical N-methyl-daspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci U S A. 1996;93:11962-11967.
11. Umbricht D, Schmid L, Koller R, et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000;57:1139-1147.
12. Gunduz-Bruce H, Reinhart RM, Roach BJ, et al. Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry. 2012;71:969-977.
13. Umbricht D, Javitt D, Novak G, et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol. 1999;2:299-304.
14. Kantrowitz JT, Hoptman MJ, Leitman DI, et al. Neural substrates of auditory emotion recognition deficits in schizophrenia. J Neurosci. 2015; 35:14909-14921.
15. Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014; 71:637-646.
16. Javitt DC. Bitopertin in schizophrenia: glass half full? Lancet Psychiatry. 2016;3:1092-1093.
17. Blaettler T, Bugarski-Kirola D, Fleischhacker WW, et al. Efficacy and safety of adjunctive bitopertin (10 and 20 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics-results from the Phase III FlashLyte Study. Schizophr Res. 2014;158:e2-e3.
18. Bugarski-Kirola D, Iwata N, Sameljak S, et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry. 2016;3:1115-1128.
19. Balu DT, Coyle JT. The NMDA receptor 'glycine modulatory site' in schizophrenia: d-serine, glycine, and beyond. Curr Opin Pharmacol. 2015; 20:109-115.
20. Weiser M, Heresco-Levy U, Davidson M, et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012;73:e728-e734.
21. Tsai G, Yang P, Chung LC, et al. d-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998;44:1081-1089.
22. Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose d-serine in the treatment of schizophrenia. Schizophr Res. 2010;121:125-130.
23. Cho SE, Na KS, Cho SJ, et al. Low d-serine levels in schizophrenia: a systematic review and meta-analysis. Neurosci Lett. 2016;634:42-51.
24. Kantrowitz JT, Woods SW, Petkova E, et al. d-Serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry. 2015;2:403-412.
25. Kantrowitz JT, Epstein ML, Lee M, et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms [Epub ahead of print March 17, 2017]. Schizophr Res. 2017. doi: 10. 1016/j. schres. 2017. 02. 027.
26. Kantrowitz JT, Epstein ML, Beggel O, et al. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist d-serine. Brain. 2016;139(Pt 12):3281-3295.
27. Guy W. ECDEU Assessment manual for psychopharmacology: revised. Rockville, MD: National Institute for Mental Health; 1976.
28. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. Psychiatr Q. 1994;65:299-322.
29. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery. Los Angeles: MATRICS Assessment, Inc; 2006.
30. Diggle PJ, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data. 2nd ed. Oxford, UK: Oxford University Press; 2002.
31. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2005;64:663-667.
32. Javitt DC, Sweet RA. Auditory dysfunction in schizophrenia: integrating clinical and basic features. Nat Rev Neurosci. 2015;16:535-550.
33. Dunayevich E, Buchanan RW, Chen CY, et al. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophr Res. 2017;182: 90-97.
34. Schoemaker JH, Jansen WT, Schipper J, et al. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the giant trial. J Clin Psychopharmacol. 2014;34:190-198.
35. Javitt DC, Duncan L, Balla A, et al. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005; 10:275-287.